Date: 2015-07-02
Type of information: Nomination
Compound:
Company: Acucela (USA - MA)
Therapeutic area: Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 2, 2015, Acucela , a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, announced that it has hired Roger Girard as Chief Strategy Officer. Having built 14 successful companies over the past 40 years in multiple industries, Girard brings deep experience in business management and will take on the newly created position at Acucela, helping to guide the Company’s growth and strategic initiatives. Girard currently serves as an executive consultant for Acucela. The Acucela Board of Directors (the “Board”) appointed Girard as Chief Strategy Officer, effective Sept. 1, 2015, at its July 2 meeting in Tokyo, Japan. Roger Girard has broad business management experience across multiple industries, including medical devices, renewable energy, manufacturing, software platforms and distribution. He most recently served as Chief Financial Officer and Co-Founder of CareCap, a Bellevue, Wash.-based company that provides cloud-based merchant processing and payment management systems for doctor-financed care facilities, and as CEO of Neuro-ID, which provides cloud-based detection of suspicious threats and behaviors. He also previously served as Chairman and CEO of IsoRay Medical , a global company that developed the process and manufactured a new Radionuclide for the treatment of malignant tumors. Girard has raised more than $325 million in investment equity over his career.
Financial terms:
Latest news:
